TRANSGENE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.322 EUR | -0.60% |
|
-8.70% | -3.50% |
| Apr. 10 | Transgene: presents vaccine results at AACR | CF |
| Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Chart calendar Transgene
6c96e96.JgGoPqe-STc636ablIg5QhZRbK6vO9_Er7XVmHVVGas.C2z5eOroPXx1tuH-xNtaFV0cBuGaDZC9zPaF3AUtX_52aeJmwNYQVlm5yQ~ee727608ab0248eeca689befce5b943b
Upcoming events on Transgene
Past events on Transgene
| 2024-04-15 | Van Lanschot Kempen Life Sciences Conference |
| 2024-04-10 12:00 pm | American Association for Cancer Research Meeting - Abstract No - LB401 |
| 2024-04-04 | Investor Access Conference |
| 2024-03-27 01:00 pm | Q4 2023 Earnings Call |
| 2024-03-27 12:45 pm | Q4 2023 Earnings Release |
| 2024-01-29 | Invest Securities Biomed Forum |
| 2024-01-14 | Oddo BHF Forum |
| 2024-01-07 | JPMorgan Healthcare Conference |
| 2023-11-07 11:45 am | Q3 2023 Earnings Release |
| 2023-10-23 | HealthTech Innovation Day |
| 2023-10-08 | Investor Access Forum |
| 2023-09-25 | Cantor Global Healthcare Conference |
| 2023-09-20 12:00 pm | Q2 2023 Earnings Call |
| 2023-09-20 11:45 am | Q2 2023 Earnings Release |
| 2023-06-27 | Stifel European Healthcare Summit |
| 2023-06-05 02:15 pm | American Society of Clinical Oncology Conference - Abstract No 6082 |
| 2023-06-03 09:00 am | American Society of Clinical Oncology Conference - Abstract No 2630 |
| 2023-06-01 | Sachs Immuno-Oncology Innovation Forum |
| 2023-05-24 | Annual General Meeting |
| 2023-05-10 11:45 am | Q1 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 42,9 15,8 172.09% | 13,7 11,4 20.46% | 9,92 87,0 -88.6% | 17,4 10,2 71.56% | 10,3 11,6 -10.83% | 7,90 7,30 8.22% |
|
EBITDA Million EUR | Released Forecast Spread | 9,10 -16,6 154.73% | -24,7 -21,6 -14.54% | -22,2 38,8 -157.23% | -21,0 -30,1 30.22% | -28,2 -32,4 12.91% | -28,5 -47,4 39.93% |
|
EBIT Million EUR | Released Forecast Spread | 7,37 -19,5 137.73% | -25,5 -23,4 -8.78% | -24,0 30,1 -179.71% | -23,5 -31,7 25.79% | -29,9 -35,4 15.53% | -30,0 -48,2 37.66% |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 8,03 7,97 0.75% | 0,00 0,00 - | -17,2 29,4 -158.57% | -19,5 -33,0 40.8% | -32,8 -34,8 5.74% | 0,00 0,00 - |
|
Net income Million EUR | Released Forecast Spread | 8,03 -29,0 127.64% | -18,8 -23,6 20.15% | -17,2 28,2 -161.1% | -19,5 -29,8 34.33% | -32,8 -34,1 3.66% | -22,3 -42,2 47.09% |
|
EPS EUR | Released Forecast Spread | 0,13 -0,18 173.48% | -0,23 -0,35 34.29% | -0,21 0,34 -161.76% | -0,21 -0,34 37.31% | -0,33 -0,34 3.88% | -0,22 -0,42 47.62% |
| Announcement Date | 20/03/19 | 11/03/20 | 10/03/21 | 16/03/22 | 16/03/23 | 27/03/24 |
Quarterly results
| Fiscal Period | December | 2022 S1 | 2022 S2 |
|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 4,26 3,80 12.03% | |
|
EBIT Million EUR | Released Forecast Spread | -15,1 -22,8 33.91% | |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -17,5 -23,3 24.79% | |
|
Net income Million EUR | Released Forecast Spread | -15,3 | -17,5 -23,3 24.72% |
|
EPS EUR | Released Forecast Spread | -0,15 | -0,18 -0,24 25% |
| Announcement Date | 07/09/22 | 16/03/23 |
More events
Past sector events for Transgene
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- TNG Stock
- Calendar Transgene
